Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.

Lal S, Carrera D, Phillips JJ, Weiss WA, Raffel C.

Neuro Oncol. 2018 Jun 14. doi: 10.1093/neuonc/noy089. [Epub ahead of print]

PMID:
29912438
2.

A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.

Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, Qin L, Garancher A, Liu KW, Mansouri S, Luu B, Thompson YY, Ramaswamy V, Peacock J, Farooq H, Skowron P, Shih DJH, Li A, Ensan S, Robbins CS, Cybulsky M, Mitra S, Ma Y, Moore R, Mungall A, Cho YJ, Weiss WA, Chan JA, Hawkins CE, Massimino M, Jabado N, Zapotocky M, Sumerauer D, Bouffet E, Dirks P, Tabori U, Sorensen PHB, Brastianos PK, Aldape K, Jones SJM, Marra MA, Woodgett JR, Wechsler-Reya RJ, Fults DW, Taylor MD.

Cell. 2018 May 31;173(6):1549. doi: 10.1016/j.cell.2018.05.033. Epub 2018 May 31. No abstract available.

PMID:
29856958
3.

GateFinder: Projection-based Gating Strategy Optimization for Flow and Mass Cytometry.

Aghaeepour N, Simonds EF, Knapp DJHF, Bruggner R, Sachs K, Culos A, Gherardini PF, Samusik N, Fragiadakis G, Bendall S, Gaudilliere B, Angst MS, Eaves CJ, Weiss WA, Fantl W, Nolan G.

Bioinformatics. 2018 May 29. doi: 10.1093/bioinformatics/bty430. [Epub ahead of print]

PMID:
29850785
4.

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA.

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

PMID:
29760046
5.

A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.

Griveau A, Seano G, Shelton SJ, Kupp R, Jahangiri A, Obernier K, Krishnan S, Lindberg OR, Yuen TJ, Tien AC, Sabo JK, Wang N, Chen I, Kloepper J, Larrouquere L, Ghosh M, Tirosh I, Huillard E, Alvarez-Buylla A, Oldham MC, Persson AI, Weiss WA, Batchelor TT, Stemmer-Rachamimov A, Suvà ML, Phillips JJ, Aghi MK, Mehta S, Jain RK, Rowitch DH.

Cancer Cell. 2018 May 14;33(5):874-889.e7. doi: 10.1016/j.ccell.2018.03.020. Epub 2018 Apr 19.

PMID:
29681511
6.

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.

Bolin S, Borgenvik A, Persson CU, Sundström A, Qi J, Bradner JE, Weiss WA, Cho YJ, Weishaupt H, Swartling FJ.

Oncogene. 2018 May;37(21):2850-2862. doi: 10.1038/s41388-018-0135-1. Epub 2018 Mar 7.

7.

Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.

Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M.

Brain. 2018 May 1;141(5):1300-1319. doi: 10.1093/brain/awy039.

PMID:
29490009
8.

A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.

Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, Qin L, Garancher A, Liu KW, Mansouri S, Luu B, Thompson YY, Ramaswamy V, Peacock J, Farooq H, Skowron P, Shih DJH, Li A, Ensan S, Robbins CS, Cybulsky M, Mitra S, Ma Y, Moore R, Mungall A, Cho YJ, Weiss WA, Chan JA, Hawkins CE, Massimino M, Jabado N, Zapotocky M, Sumerauer D, Bouffet E, Dirks P, Tabori U, Sorensen PHB, Brastianos PK, Aldape K, Jones SJM, Marra MA, Woodgett JR, Wechsler-Reya RJ, Fults DW, Taylor MD.

Cell. 2018 Feb 22;172(5):1050-1062.e14. doi: 10.1016/j.cell.2018.01.038. Erratum in: Cell. 2018 May 31;173(6):1549.

PMID:
29474906
9.

Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma.

Ilkhanizadeh S, Sabelström H, Miroshnikova YA, Frantz A, Zhu W, Idilli A, Lakins JN, Schmidt C, Quigley DA, Fenster T, Yuan E, Trzeciak JR, Saxena S, Lindberg OR, Mouw JK, Burdick JA, Magnitsky S, Berger MS, Phillips JJ, Arosio D, Sun D, Weaver VM, Weiss WA, Persson AI.

Mol Cancer Res. 2018 May;16(5):777-790. doi: 10.1158/1541-7786.MCR-17-0413. Epub 2018 Feb 5.

PMID:
29431617
10.

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

An Z, Aksoy O, Zheng T, Fan QW, Weiss WA.

Oncogene. 2018 Mar;37(12):1561-1575. doi: 10.1038/s41388-017-0045-7. Epub 2018 Jan 11. Review.

11.

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.

J Clin Invest. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4.

12.

Neuroblastoma Metastases: Leveraging the Avian Neural Crest.

Zheng T, Ménard M, Weiss WA.

Cancer Cell. 2017 Oct 9;32(4):395-397. doi: 10.1016/j.ccell.2017.09.012.

PMID:
29017050
13.

Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer.

Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC, Matsumoto K, Lu K, Bergers G, Sali A, Weiss WA, Aghi MK.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8685-E8694. doi: 10.1073/pnas.1701821114. Epub 2017 Sep 26.

14.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.

Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB.

Genes Dev. 2017 Jun 15;31(12):1212-1227. doi: 10.1101/gad.300079.117. Epub 2017 Jul 19.

15.

CNS Anticancer Drug Discovery and Development: 2016 conference insights.

Levin VA, Abrey LE, Heffron TP, Tonge PJ, Dar AC, Weiss WA, Gallo JM.

CNS Oncol. 2017 Jul 18. doi: 10.2217/cns-2017-0014. [Epub ahead of print]

16.

Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.

Rodriguez-Blanco J, Pednekar L, Penas C, Li B, Martin V, Long J, Lee E, Weiss WA, Rodriguez C, Mehrdad N, Nguyen DM, Ayad NG, Rai P, Capobianco AJ, Robbins DJ.

Oncogene. 2017 Nov 9;36(45):6306-6314. doi: 10.1038/onc.2017.232. Epub 2017 Jul 17.

17.

Inhibiting 4EBP1 in Glioblastoma.

Fan QW, Nicolaides TP, Weiss WA.

Clin Cancer Res. 2018 Jan 1;24(1):14-21. doi: 10.1158/1078-0432.CCR-17-0042. Epub 2017 Jul 10. Review.

PMID:
28696243
18.

Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD.

Cancer Cell. 2017 Jun 12;31(6):737-754.e6. doi: 10.1016/j.ccell.2017.05.005.

19.

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA.

Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.

20.

Breast density estimation from high spectral and spatial resolution MRI.

Li H, Weiss WA, Medved M, Abe H, Newstead GM, Karczmar GS, Giger ML.

J Med Imaging (Bellingham). 2016 Oct;3(4):044507. doi: 10.1117/1.JMI.3.4.044507. Epub 2016 Dec 28.

21.

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T.

J Neurooncol. 2017 Feb;131(3):495-505. doi: 10.1007/s11060-016-2333-4. Epub 2016 Nov 15.

22.

Cholesterol: An Achilles' Heel for Glioblastoma?

An Z, Weiss WA.

Cancer Cell. 2016 Nov 14;30(5):653-654. doi: 10.1016/j.ccell.2016.10.011.

23.

Neuroblastoma.

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA.

Nat Rev Dis Primers. 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78. Review.

PMID:
27830764
24.

IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.

Rinkenbaugh AL, Cogswell PC, Calamini B, Dunn DE, Persson AI, Weiss WA, Lo DC, Baldwin AS.

Oncotarget. 2016 Oct 25;7(43):69173-69187. doi: 10.18632/oncotarget.12507.

25.

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.

Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T.

Oncotarget. 2017 Jan 3;8(1):583-595. doi: 10.18632/oncotarget.11882.

26.

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, Workman P, Chesler L.

Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544.

27.

Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA.

Neuro Oncol. 2017 Feb 1;19(2):153-161. doi: 10.1093/neuonc/now101. Review.

28.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD.

Lancet Oncol. 2016 Apr;17(4):484-495. doi: 10.1016/S1470-2045(15)00581-1. Epub 2016 Mar 12.

29.

Generating trunk neural crest from human pluripotent stem cells.

Huang M, Miller ML, McHenry LK, Zheng T, Zhen Q, Ilkhanizadeh S, Conklin BR, Bronner ME, Weiss WA.

Sci Rep. 2016 Jan 27;6:19727. doi: 10.1038/srep19727.

30.

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):395. doi: 10.1007/s11060-015-2024-6. No abstract available.

PMID:
26782702
31.

Divergent clonal selection dominates medulloblastoma at recurrence.

Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FM, Ramaswamy V, Lindsay PE, Jelveh S, Donovan LK, Wang X, Luu B, Zayne K, Li Y, Mayoh C, Thiessen N, Mercier E, Mungall KL, Ma Y, Tse K, Zeng T, Shumansky K, Roth AJ, Shah S, Farooq H, Kijima N, Holgado BL, Lee JJ, Matan-Lithwick S, Liu J, Mack SC, Manno A, Michealraj KA, Nor C, Peacock J, Qin L, Reimand J, Rolider A, Thompson YY, Wu X, Pugh T, Ally A, Bilenky M, Butterfield YS, Carlsen R, Cheng Y, Chuah E, Corbett RD, Dhalla N, He A, Lee D, Li HI, Long W, Mayo M, Plettner P, Qian JQ, Schein JE, Tam A, Wong T, Birol I, Zhao Y, Faria CC, Pimentel J, Nunes S, Shalaby T, Grotzer M, Pollack IF, Hamilton RL, Li XN, Bendel AE, Fults DW, Walter AW, Kumabe T, Tominaga T, Collins VP, Cho YJ, Hoffman C, Lyden D, Wisoff JH, Garvin JH Jr, Stearns DS, Massimi L, Schüller U, Sterba J, Zitterbart K, Puget S, Ayrault O, Dunn SE, Tirapelli DP, Carlotti CG, Wheeler H, Hallahan AR, Ingram W, MacDonald TJ, Olson JJ, Van Meir EG, Lee JY, Wang KC, Kim SK, Cho BK, Pietsch T, Fleischhack G, Tippelt S, Ra YS, Bailey S, Lindsey JC, Clifford SC, Eberhart CG, Cooper MK, Packer RJ, Massimino M, Garre ML, Bartels U, Tabori U, Hawkins CE, Dirks P, Bouffet E, Rutka JT, Wechsler-Reya RJ, Weiss WA, Collier LS, Dupuy AJ, Korshunov A, Jones DT, Kool M, Northcott PA, Pfister SM, Largaespada DA, Mungall AJ, Moore RA, Jabado N, Bader GD, Jones SJ, Malkin D, Marra MA, Taylor MD.

Nature. 2016 Jan 21;529(7586):351-7. doi: 10.1038/nature16478. Epub 2016 Jan 13.

32.

Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo.

Yu D, Dong Z, Gustafson WC, Ruiz-González R, Signor L, Marzocca F, Borel F, Klassen MP, Makhijani K, Royant A, Jan YN, Weiss WA, Guo S, Shu X.

Protein Sci. 2016 Feb;25(2):308-15. doi: 10.1002/pro.2843. Epub 2015 Dec 31.

33.

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):385-93. doi: 10.1007/s11060-015-1939-2. Epub 2015 Sep 18. Erratum in: J Neurooncol. 2016 Feb;126(3):395.

34.

STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.

Lau J, Ilkhanizadeh S, Wang S, Miroshnikova YA, Salvatierra NA, Wong RA, Schmidt C, Weaver VM, Weiss WA, Persson AI.

Cancer Res. 2015 Oct 15;75(20):4302-11. doi: 10.1158/0008-5472.CAN-14-3331. Epub 2015 Aug 17.

35.

EAG2 potassium channel with evolutionarily conserved function as a brain tumor target.

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman MA, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY.

Nat Neurosci. 2015 Sep;18(9):1236-46. doi: 10.1038/nn.4088. Epub 2015 Aug 10.

36.

Preliminary assessment of dispersion versus absorption analysis of high spectral and spatial resolution magnetic resonance images in the diagnosis of breast cancer.

Weiss WA, Medved M, Karczmar GS, Giger ML.

J Med Imaging (Bellingham). 2015 Apr;2(2):024502. doi: 10.1117/1.JMI.2.2.024502. Epub 2015 May 7.

37.

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.

Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC.

Front Oncol. 2015 May 12;5:111. doi: 10.3389/fonc.2015.00111. eCollection 2015.

38.

EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.

Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T.

Oncotarget. 2015 Sep 8;6(26):21993-2005.

39.

Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.

Mack SC, Agnihotri S, Bertrand KC, Wang X, Shih DJ, Witt H, Hill N, Zayne K, Barszczyk M, Ramaswamy V, Remke M, Thompson Y, Ryzhova M, Massimi L, Grajkowska W, Lach B, Gupta N, Weiss WA, Guha A, Hawkins C, Croul S, Rutka JT, Pfister SM, Korshunov A, Pekmezci M, Tihan T, Philips JJ, Jabado N, Zadeh G, Taylor MD.

Clin Cancer Res. 2015 Aug 15;21(16):3750-8. doi: 10.1158/1078-0432.CCR-14-2650. Epub 2015 May 8.

40.

A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition.

Meyerowitz JG, Weiss WA, Gustafson WC.

Mol Cell Oncol. 2015 Feb 25;2(2):e975641. doi: 10.4161/23723556.2014.975641. eCollection 2015 Apr-Jun.

41.

The genetics of splicing in neuroblastoma.

Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA.

Cancer Discov. 2015 Apr;5(4):380-95. doi: 10.1158/2159-8290.CD-14-0892. Epub 2015 Jan 30.

42.

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.

Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, Fraser M, Tse K, Poon R, Shih DJ, Baskin B, Ray PN, Bouffet E, Dirks P, von Bueren AO, Pfaff E, Korshunov A, Jones DT, Northcott PA, Kool M, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognár L, Cho BK, Eberhart CG, Conter CF, Fouladi M, French PJ, Grajkowska WA, Gupta N, Hauser P, Jabado N, Vasiljevic A, Jung S, Kim SK, Klekner A, Kumabe T, Lach B, Leonard JR, Liau LM, Massimi L, Pollack IF, Ra YS, Rubin JB, Van Meir EG, Wang KC, Weiss WA, Zitterbart K, Bristow RG, Alman B, Hawkins CE, Malkin D, Clifford SC, Pfister SM, Taylor MD, Tabori U.

Acta Neuropathol Commun. 2014 Dec 24;2:174. doi: 10.1186/s40478-014-0174-y.

43.

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.

Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, Ruddle R, Raynaud FI, Howell L, Kwok C, Joshi A, Nicholson SL, Crosier S, Ellison DW, Wharton SB, Robson K, Michalski A, Hargrave D, Jacques TS, Pizer B, Bailey S, Swartling FJ, Weiss WA, Chesler L, Clifford SC.

Cancer Cell. 2015 Jan 12;27(1):72-84. doi: 10.1016/j.ccell.2014.11.002. Epub 2014 Dec 18.

44.

Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.

Li N, Maly DJ, Chanthery YH, Sirkis DW, Nakamura JL, Berger MS, James CD, Shokat KM, Weiss WA, Persson AI.

Mol Cancer Ther. 2015 Feb;14(2):419-28. doi: 10.1158/1535-7163.MCT-14-0526. Epub 2014 Dec 18.

45.

Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan Q, Weiss WA.

Cell Rep. 2014 Nov 6;9(3):1034-46. doi: 10.1016/j.celrep.2014.09.046. Epub 2014 Oct 23.

46.

Drugging MYCN through an allosteric transition in Aurora kinase A.

Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA.

Cancer Cell. 2014 Sep 8;26(3):414-427. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28.

47.

When deletions gain functions: commandeering epigenetic mechanisms.

Chen J, Weiss WA.

Cancer Cell. 2014 Aug 11;26(2):160-1. doi: 10.1016/j.ccr.2014.07.021.

48.

Glial progenitors as targets for transformation in glioma.

Ilkanizadeh S, Lau J, Huang M, Foster DJ, Wong R, Frantz A, Wang S, Weiss WA, Persson AI.

Adv Cancer Res. 2014;121:1-65. doi: 10.1016/B978-0-12-800249-0.00001-9. Review.

49.

An improved monomeric infrared fluorescent protein for neuronal and tumour brain imaging.

Yu D, Gustafson WC, Han C, Lafaye C, Noirclerc-Savoye M, Ge WP, Thayer DA, Huang H, Kornberg TB, Royant A, Jan LY, Jan YN, Weiss WA, Shu X.

Nat Commun. 2014 May 15;5:3626. doi: 10.1038/ncomms4626.

50.

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.

Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, von Deimling A, Davis T, Weiss WA, Loeffler M, Reifenberger G; German Glioma Network.

Int J Cancer. 2014 May 15;134(10):2437-47. Erratum in: Int J Cancer. 2016 Aug 15;139(4):E9.

Supplemental Content

Loading ...
Support Center